Remove tag healthcare-access
article thumbnail

Generative AI with Google Lens to detect counterfeits in pharma

Express Pharma

Generative AI will be used to create unique invisible image tags for each product (like UID). This can be done by training the AI on a dataset of existing batch numbers, allowing it to generate new, unique invisible image tags on brand logo / brand name that cannot be replicated by counterfeiters 2.

article thumbnail

IBM sells off large parts of Watson Health business

pharmaphorum

A private equity group has agreed to take over most of IBM Watson Health, seven years after the business was launched with a pledge to revolutionise healthcare data analysis. IBM said it “remains committed to Watson, our broader AI business, and to the clients and partners we support in healthcare IT.”

Cerner 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NICE reaches a deal with Roche on access to oral SMA drug Evrysdi

pharmaphorum

Roche’s oral treatment Evrysdi for the rare genetic disease spinal muscular atrophy (SMA) will be made available on the NHS in England, after NICE reached a three-year access agreement with the company. million price tag make it is the most expensive treatment ever approved for NHS funding.

97
article thumbnail

Orphan drugs and where to launch them: The keys to Europe’s forgotten territories

Pharmaceutical Technology

Due to the high price tags associated with these speciality medicines, innovators have naturally favoured big markets with high GDP such as the US and EU-5 (Germany, France, Spain, Italy, and the UK). The challenge of providing adequate access to the peripheral EU markets is quite evident. Europe’s forgotten territories.

article thumbnail

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

This is not the first treatment to come with a high price tag. Partly in response to such drugs, risk-sharing agreements (RSAs) have increased in popularity and aim to mitigate the risks of including high-cost drugs on reimbursement lists and healthcare plans.

105
105
article thumbnail

NICE says yes to Novartis’ multiple sclerosis therapy Kesimpta

pharmaphorum

NICE’s final appraisal document for Kesimpta will be followed by technology appraisal guidance (TAG) that will pave the way for NHS prescribing in England and Wales. The Scottish Medicines Consortium is expected to publish its final advice on the drug later this year.

Hospitals 111
article thumbnail

Biotech titans Bengaluru and Hyderabad fortify India’s dominance

Express Pharma

Bengaluru’s social infrastructure, characterised by top-tier educational institutions like the Indian Institute of Science, facilitates access to a highly skilled talent pool and an organically growing innovation system (4).